BLA 761238 · Tg Therapeutics, INC
Briumvi
Ublituximab-Xiiy · Intravenous · CD20-directed Cytolytic Antibody
NovelCDER novel approval, Dec 28, 2022: To treat relapsing forms of multiple sclerosis
Last checked: Nov 20, 2026Latest source record: Jan 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
Dec 28, 2022
Approved uses
1
Original approval plus efficacy supplements
Registered trials
46
11 Phase 3, 13 recruiting
FAERS reports
3,894
932 serious, 67 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 19, 2026.
BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).
Mechanism: The precise mechanism by which ublituximab-xiiy exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ublituximab-xiiy results in cell lysis through mechanisms including antibody-dependent cellular cytolysis and complement-dependent cytolysis.
Therapeutic areas: Hematology and blood cancers · Neurology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- BRIUMVI · UBLITUXIMAB-XIIY 25 MG/ML · INJECTABLE, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ublituximab" as an intervention, any sponsor and status, largest first.
- An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisPivotal-lookingActive, not recruiting
TG Therapeutics, Inc.Industry
NCT04130997 · 1,100 participants (planned) · Start Nov 18, 2019 · Primary completion May 31, 2032
Drug: Ublituximab · For: Relapsing Multiple Sclerosis (RMS)
Sites: Pasadena, California; Denver, Colorado; Miami, Florida · 86 sites in all
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPivotal-lookingRecruiting
TG Therapeutics, Inc.Industry
NCT05877963 · 800 participants (planned) · Start Jun 13, 2023 · Primary completion Jan 21, 2027
Drug: Ublituximab; Placebo · For: Relapsing Multiple Sclerosis
Sites: Birmingham, Alabama; Cullman, Alabama; Orange, California · 51 sites in all
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMSPivotal-lookingActive, not recruiting
The Cleveland ClinicAcademic, hospital or other
NCT03535298 · 800 participants (planned) · Start Jan 3, 2019 · Primary completion Jul 30, 2027
Drug: Early Highly Effective Therapies Group; Escalation Therapies Group · For: Multiple Sclerosis, Relapsing-Remitting
Sites: Aurora, Colorado; Minneapolis, Minnesota; Rochester, Minnesota · 30 sites in all
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaPivotal-lookingTerminated
TG Therapeutics, Inc.Industry
NCT02793583 · 710 participants · Start May 25, 2016 · Primary completion May 31, 2022
Drug: Ublituximab; Umbralisib and 1 more · For: Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma and 2 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 168 sites in all
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaPivotal-lookingTerminated
TG Therapeutics, Inc.Industry
NCT02612311 · 603 participants · Start Nov 19, 2015 · Primary completion Feb 22, 2023
Drug: Obinutuzumab; Ublituximab and 2 more · For: Chronic Lymphocytic Leukemia
Sites: Huntsville, Alabama; Mobile, Alabama; Chandler, Arizona · 154 sites in all
- Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )Pivotal-lookingCompleted
TG Therapeutics, Inc.Industry
NCT03277261 · 549 participants · Start Sep 19, 2017 · Primary completion Jul 23, 2020
Drug: Ublituximab; Teriflunomide and 2 more · For: Relapsing Multiple Sclerosis (RMS)
Sites: Carlsbad, California; Long Beach, California; Pasadena, California · 14 sites in all
- Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)Pivotal-lookingCompleted
TG Therapeutics, Inc.Industry
NCT03277248 · 545 participants · Start Aug 25, 2017 · Primary completion Aug 4, 2020
Drug: Ublituximab; Teriflunomide and 2 more · For: Relapsing Multiple Sclerosis (RMS)
Sites: Phoenix, Arizona; Aurora, Colorado; Tampa, Florida · 13 sites in all
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Pivotal-lookingActive, not recruiting
TG Therapeutics, Inc.Industry
NCT07211633 · 360 participants (planned) · Start Jul 9, 2025 · Primary completion Oct 31, 2026
Drug: Ublituximab; Ublituximab · For: Relapsing Multiple Sclerosis
Sites: Banja Luka, Bosnia and Herzegovina; Bihać, Bosnia and Herzegovina; Mostar, Bosnia and Herzegovina · 48 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- infusion related reaction1,435
- fatigue238
- headache124
- malaise116
- pain109
- urinary tract infection103
- illness100
- multiple sclerosis relapse99
- asthenia94
- gait disturbance90
- inappropriate schedule of product administration88
- maternal exposure during pregnancy82
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 10 |
| 2019 | 1 |
| 2021 | 48 |
| 2022 | 26 |
| 2023 | 247 |
| 2024 | 1,012 |
| 2025 | 1,783 |
| 2026 | 760 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Briumvi (Ublituximab-Xiiy)
2024 spending
$8.0M
Beneficiaries
155
301 claims
Per beneficiary
$51,582
$1,752.86 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,791,742 |
| 2024 | $7,995,163 |
Part B: Briumvi (Ublituximab-Xiiy) · HCPCS J2329
2024 spending
$25.5M
Beneficiaries
518
1,120 claims
Per beneficiary
$49,274
2024 ASP limit $68.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $4,963,901 |
| 2024 | $25,523,924 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.
Samjoo IA, Drudge C, Walsh S, et al. · J Comp Eff Res 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials.
Moloney E, Mashayekhi A, Sharma S, et al. · Front Neurol 2024 · Systematic Review
- The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis?
Doggrell SA · Expert Opin Biol Ther 2022 · Meta-Analysis
- Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach.
Roeker LE, Feldman TA, Soumerai JD, et al. · Clin Cancer Res 2022 · Clinical Trial, Phase II, Research Support, N.I.H., Extramural
- Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders.
Kaegi C, Wuest B, Crowley C, et al. · Front Immunol 2021 · Systematic Review
Sponsor: Tg Therapeutics, INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.